West Pharmaceutical Services (WST) Depreciation & Amortization (CF) (2009 - 2026)

West Pharmaceutical Services (WST) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $45.7 million the latest figure, recorded in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 12.01% year-over-year to $45.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $179.0 million (up 12.58% YoY) and the FY2025 annual result came in at $168.6 million, up 11.07% from the prior year.
• Depreciation & Amortization (CF) advanced to $45.7 million in Q2 2026 per WST's latest filing, from $44.6 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for WST reached as high as $46.4 million in Q4 2025 and fell as low as $28.7 million in Q1 2022.
• A 5-year average of $36.7 million and a median of $36.4 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) fell 6.81% — and 2023, when it increased 20.42%.
• Year by year, Depreciation & Amortization (CF) stood at $30.1 million in 2022, then advanced by 14.95% to $34.6 million in 2023, then increased by 15.03% to $39.8 million in 2024, then gained by 16.58% to $46.4 million in 2025, then declined by 1.51% to $45.7 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $45.7 million, $44.6 million, and $46.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.